Reviewing PMV Pharmaceuticals (NASDAQ:PMVP) & Aurinia Pharmaceuticals (NASDAQ:AUPH)

PMV Pharmaceuticals (NASDAQ:PMVP) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Risk and Volatility

PMV Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Earnings & Valuation

This table compares PMV Pharmaceuticals and Aurinia Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$58.71 million	($1.60)	-0.84
Aurinia Pharmaceuticals	$265.81 million	7.99	$5.75 million	$0.56	28.77

Aurinia Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for PMV Pharmaceuticals and Aurinia Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	1	0	2.00
Aurinia Pharmaceuticals	0	3	2	0	2.40

PMV Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 270.37%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 9.66%. Given PMV Pharmaceuticals’ higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Profitability

This table compares PMV Pharmaceuticals and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-55.34%	-51.01%
Aurinia Pharmaceuticals	23.31%	20.06%	13.81%

Insider and Institutional Ownership

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats PMV Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.